Poulton Stuart 4
4 · Karyopharm Therapeutics Inc. · Filed Feb 20, 2024
Insider Transaction Report
Form 4
Poulton Stuart
EVP, Chief Development Officer
Transactions
- Sale
Common Stock
2024-02-15$1.33/sh−5,748$7,645→ 163,871 total - Sale
Common Stock
2024-02-15$1.40/sh−99$139→ 163,772 total
Footnotes (1)
- [F1]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.